Neuromodulation Pioneer WISE Closes EUR 15M Series C Financing Round to Launch Second Product, SCS EXPERT, for Chronic Pain
SCS EXPERT is the first expandable percutaneous lead for neuromodulation treatment for chronic pain
New investors, led by CDP Venture Capital, and including Indaco Ventures I and EUREKA! Venture, join existing participating investors in financing round
Adds to EUR 2.3M grant earlier in 2020 from the European Commission to launch SCS EXPERT
WISE Srl, a medical device company developing next-generation implantable leads for neuromonitoring, neuromodulation and brain-machine interfacing, today announced the closing of a EUR 15 million Series C financing round. New investors, led by CDP Venture Capital SGR, and including Indaco Ventures I Fund and EUREKA! Venture SGR, joined existing investors participating in this round – Principia SGR, New Frontier, Atlante Seed and Atlante Ventures (funds managed by Indaco Venture Partners SGR), High Tech Gründerfonds and F3F.
The proceeds will be partially used to accelerate the development of the Company’s second product, SCS EXPERT (EXpandable PERcuTaneous), a percutaneously implantable multi-column paddle lead for Spinal Cord Stimulation (SCS). The funds will also support the upcoming launch of its first product, WISE Cortical Strip (WCS), a single use medical device for IntraOperative Neurophysiological Monitoring during brain tumor and epilepsy surgeries, which is anticipating the granting of its CE mark.
This financing adds to the recent European Commission grant of EUR 2.3 million given to WISE in July 2020, to support the development and launch of SCS EXPERT within the EIC Accelerator program of Horizon 2020.
“We are delighted with the support we have received for our latest funding round and welcome our new investors,” said Luca Ravagnan, CEO at WISE. “With this additional funding, we will be able to accelerate our plans to launch SCS EXPERT, as we make progress toward FDA clearance and market launch.”
He added, “With support from our engaged investors,
7thirty Capital and Delta Emerald Ventures co-led the investment with participation from Welcan Capital, Arcview Collective Fund, and others
NOVATO, Calif., Sept. 29, 2020 /PRNewswire/ — Trym, a pioneering cannabis cultivation software company, is pleased to announce the completion of its $3.1M seed funding round of financing. In addition to an initial friends and family of $1M, 7thirty Capital and Delta Emerald Ventures co-led the preferred round of $2.1M. Welcan Capital, Arcview Collective Fund, and others also participated in the oversubscribed round. The funding will enable Trym to make further software advancements and expand its trusted farm management platform into new markets.
“Our investors are a perfect match with Trym’s DNA,” said Matt Mayberry, CEO and co-founder, Trym. “They understand that connectivity is the future of cannabis agriculture and that to stay in the game, commercial cultivators have to closely track and manage all aspects of their business. A disruption is happening in the market and we’re helping to drive it.”
Trym currently operates in 14 U.S. states and works with more than 80 of the largest cultivators and multi-state operators in the country.
Intense competition in the cultivation supply chain pushes down on prices and forces operators to improve their production efficiency to stay competitive. Trym addresses the needs of scaling organizations and will use the capital to continue improving its cultivation-focused platform. The funds will also be deployed for strategic software integrations with complimentary supply chain software and hardware systems.
“The growth opportunity in the cannabis cultivation software market is very exciting for us,” said Micah Tapman, Managing Partner at 7thirty Capital. “Trym is disrupting cannabis cultivation with a comprehensive software platform that streamlines business and connects the whole team for more efficient farm management. We have watched Trym grow since 2019,